Researchers design wearable tech that can sense glucose levels more accurately

Original Article ↗ Hacker News Discussion ↗

Researchers at the University of Waterloo claim to have built a wrist‑worn, radar‑based device that can measure blood glucose non‑invasively, potentially eliminating the need for needles and current continuous glucose monitors (CGMs). Commenters note that non‑invasive glucose sensing has been a “holy grail” for decades and express strong skepticism, pointing out the lack of published clinical accuracy data, past failures like GlucoWatch and Theranos‑style hype, and the technical challenge of extracting a clean glucose signal from noisy biological data. Many diabetics say current CGMs already provide life‑changing benefits, arguing that any new device must match them on accuracy and reliability, while others see a less precise, needle‑free sensor as potentially useful for type 2 diabetes management, athletic performance, and general metabolic health tracking.

Current CGMs and Quality-of-Life Tradeoffs

  • Many people with Type 1 say modern CGMs (Dexcom, Libre/Freestyle) are already life‑changing, especially in closed‑loop setups with pumps; A1c and time‑in‑range can reach near‑non‑diabetic levels.
  • Main pain points: sensor cost, adhesive/skin irritation, occasional sensor inaccuracies, variability between patches, startup delay, shower interference, “compression lows,” and latency (≈10–15 minutes).
  • Several users say the invasiveness of current CGMs is minor compared to fingersticks; for some, the adhesive is worse than the tiny filament.
  • For managing kids with T1, going from one poke every 10–15 days to zero would still be a big deal.

Accuracy, Clinical Relevance, and Overhyping

  • Thread repeatedly notes the press release overclaims relative to the paper: the research mainly demonstrates a more sensitive RF “metasurface” antenna on simple solutions, not validated human glucose readings.
  • No clear, in‑body accuracy metrics vs. gold‑standard blood tests are provided; some references to “~90%” accuracy are vague.
  • People stress that T1 use and closed‑loop dosing require high, proven accuracy; CGMs already struggle outside normal ranges.
  • Several point out that non‑invasive glucose sensing has been a “holy grail” for decades, with many failed startups and past products (e.g., GlucoWatch) and even apparent scams.

Technical Approach and Limitations

  • Device uses mm‑wave / RF “near‑field” sensing with a metasurface (array of resonant antennas) to detect changes in dielectric properties of blood correlated with glucose.
  • Experts note the basic antenna/metasurface idea is not new; the challenge is extracting a specific glucose signal from complex, noisy tissue where many factors alter dielectric properties.
  • RF‑based methods are not chemically specific to glucose, unlike some optical/IR approaches; concern that other solutes or physiological changes could confound readings.

AI / Algorithm Claims

  • Marketing language about “artificial intelligence algorithms” is widely viewed as inflated; commenters expect mostly conventional signal processing, maybe simple ML (e.g., regression, random forests).

Potential Markets and Use Cases

  • Even if not accurate enough for T1 dosing, a wrist device could be useful for:
    • Type 2/pre‑diabetes management and lifestyle feedback.
    • “Glucose‑curious” non‑diabetics, athletes, and weight‑management use.
  • Some expect strong consumer demand if integrated into mass‑market watches, though others warn this space is crowded with dubious products.

Overall Sentiment

  • Enthusiasm for the concept and for any credible non‑invasive progress.
  • Strong skepticism that this specific work is close to replacing current CGMs; calls to wait for robust, published clinical data before believing the hype.